Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nebulized vs Inhaled Albuterol in Lymphangioleiomyomatosis
NCT01799538Phase 2Recruiting
- Sponsor
- National Heart, Lung, and Blood Institute
- Start
- Jun 2013
- Primary completion
- Nov 2027
- Countries
- 1
01
Overview
A Phase 2 trial of albuterol dry powder inhaler in lymphangioleiomyomatosis (LAM), sponsored by National Heart, Lung, and Blood Institute. Started Jun 2013; status: recruiting.
02
Drugs
albuterol dry powder inhaler
03
Conditions
lymphangioleiomyomatosis (LAM)
Beyond the preview
Go deeper on NCT01799538.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01799538.